Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA-approved test determines both whether prostate cancer has metastasized and where those tumor cells can be found.
Orgovyx (relugolix) may eliminate some patients’ need to visit a clinic for treatments administered by a health care provider.
Here’s a list of the approved drugs to treat prostate cancer. Click on any of the medications for more info on dosing, side effects a...
A larger Phase II trial has been launched to evaluate the combination’s efficacy and safety.
While disease progression was higher in Black men, their rates of metastasis and mortality were similar to those of white men.
Researchers found that aggressive Gleason grade group 5 prostate cancer has different subtypes with varying risks.
The benefit of reduced mortality must be balanced against the harms of overdiagnosis.
It was 27% more accurate than the standard approach at detecting any metastases.
PARP inhibitor delays disease progression for patients with harmful BRCA and related mutations.
More than 40% of people treated with the PARP inhibitor saw tumor shrinkage.
Gavin Ha, PhD, receives grant to study whether noninvasive procedure can help monitor and predict how patients will respond to therapy
Men who took Zytiga had higher quality of life scores and less pain than those treated with chemotherapy.
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
The drug was previously approved for castration-resistant prostate cancer.
First targeted therapy may prolong survival of men with advanced prostate cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.